332, P < .0001, OR 1.931 [CI 1.448–2.575]). Considering only young populations with actual overweight-obesity, defined by weight/height measurement and by BMI criteria, perceived overweight-obesity is not significantly associated with headache (χ2 1.472, P = .225, OR 1.551 [CI 0.827–2.907]). Young populations with actual normal weight, defined by weight/height measurement and by BMI criteria, perceived overweight-obesity is significantly associated
with headache (χ2 18.710, P < .0001, OR 2.181 [CI 1.537–3.097]). Alvelestat concentration According to our results, headache does not have a straightforward association with overweight-obesity in youngsters when considering the objective measurement criterion. We observed a greater association of an individual perception of overweight-obesity with headache. As Chai and colleagues appropriately address in their review, it is possible that epidemiological reports could be biased by the actual definition of overweight-obesity, namely by the self-reported and not actually measured weight and height. Since headache is reported with a greater frequency check details in younger population groups with an erroneous perception of excessive weight, the challenge could be that prevention programs designed to address specific behaviors that can affect the development of obesity should take into account the behavioral correlates of body weight perception. This demands the planning
of a more articulated approach when targeting subgroups, Inositol monophosphatase 1 considering also the possible effects of both environment and habits. “
origin of a case of unilateral burning mouth syndrome, previously diagnosed as psychogenic, was ascertained by intra-oral mucosa biopsy, which showed a severe sensory fibers damage, probably caused by maxillary anesthetic block and dental surgery. “
“Although the drug topiramate initially was developed for the treatment of epilepsy and received its first US Food and Drug Administration (FDA) approval for that purpose, it subsequently was shown to be effective for the prevention of migraine headaches and is FDA approved for that indication as well. Migraine and epilepsy share a considerable number of biologic and clinical features, and it follows that certain of the newer anti-epileptic drugs are effective for the prevention of migraine attacks as well as seizures. Precisely how topiramate prevents migraine is unclear, but generally speaking, it appears to reduce the genetically derived brain hyperexcitability that provokes migraine attacks in susceptible individuals. While the clinical trials for migraine prevention that earned topiramate its FDA approval involved patients with episodic migraine (ie, less than 15 headache days per month), 1 large, randomized, placebo-controlled study indicated that topiramate may be effective for patients with chronic migraine as well (ie, 15 or more headache days per month).